查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425078

披衣菌感染感染诊断市场 – 2024 年至 2029 年预测

Chlamydia Infection Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年披衣菌感染感染诊断市场规模为1211,526,000美元。

披衣菌感染诊断是确认个体中是否有披衣菌感染衣原体细菌的测试和治疗。披衣菌感染是一种性行为感染疾病，并且无症状性，因此即使您没有表现出披衣菌感染症状，您仍然可能被感染。因此，披衣菌感染的早期诊断和早期治疗非常重要。

披衣菌感染感染诊断市场的推动要素

影响披衣菌感染感染诊断市场成长的主要因素是测试频率的增加以及快速可靠测试的需求的增加。分子诊断在披衣菌感染感染诊断产业中势头强劲。它提供了多种技术优势，包括快速的照护现场检测选项，以满足不断增长的需求。此外，各种政府措施也促进了披衣菌感染感染诊断市场的成长。例如，英国政府的国家披衣菌感染筛检计画（NCSP）。

性行为感染传染病的流行

沙眼衣原体感染正在迅速增加。这种增加的主要原因是性行为的变化以及个人对披衣菌感染本质上是性传染病的认识缺乏。如果不及时治疗，披衣菌感染会影响人体并导致严重的健康併发症。因此，对准确、及时诊断的需求显着增加。此外，越来越需要新的诊断方法来治疗抗抗生素的披衣菌感染菌株。在此背景下，披衣菌感染感染诊断产业的公司正在专注于新产品的开发。

披衣菌感染感染增加

由于个人意识的缺乏和性行为的改变，沙眼衣原体感染的人数正在显着增加。例如，根据 CDC 2021 年发布的资料，报告了 1,644,416 例披衣菌感染病例，使其成为美国最受欢迎的疾病之一。这意味着2020年美国每10万人中有495.5例。这种疾病的发生率不断上升，增加了先进测试在诊断和治疗中的使用，预计将推动披衣菌感染感染诊断市场的成长。

全球机构的支持不断增加

根据世界卫生组织2020年发布的报告，世界卫生组织计画减少全球性传染感染的流行。正因为如此，披衣菌感染的诊断和治疗显着增加。此外，各议会和大学正在努力促进各种性传染病的诊断和治疗，尤其披衣菌感染，这种疾病对女性的身体有长期影响。如果及早诊断，披衣菌感染很容易治疗。世界各地正在采取各种政府措施来根除披衣菌感染病例。

核酸增幅检查(NAAT) 日益普及

核酸增幅检查是一种检测 DNA 的分子检验。为了诊断披衣菌感染感染，NAAT 检测生物样本中的披衣菌感染衣原体 RNA 或 DNA。 NAAT 方法更灵敏和特异性，适用于女性阴道拭子和男性和女性尿液。此外，2022 年 3 月，Binx Health IO CT/N 检测获得 FDA核准，可用于各种最终用户的照护现场环境。产品核可进一步加强了 NAAT 在披衣菌感染感染诊断市场的地位。

先进诊断技术的开发

分子诊断测试等各种新兴诊断技术的发展是推动披衣菌感染感染诊断市场的主要因素之一。这导致了各种准确且灵敏的披衣菌感染诊断测试的发展。例如，罗氏与 NICE 合作推出了披衣菌感染诊断的分子诊断指南。这些指南有助于英国诊断测试的标准化。全球医疗保健支出的增加带来了各种投资，包括技术先进的诊断设施。

扩大在医院的应用

医院占据披衣菌感染诊断市场的最大份额。便捷的基础设施和合格的医生是这项发展的主要成长要素。需要医院诊断的大量患者以及在医院轻鬆获得披衣菌感染筛检测试正在刺激披衣菌感染诊断市场的成长。此外，由于披衣菌感染衣原体分子诊断的应用（包括NAAT的应用）的快速增加，因此预计诊断中心也将显着增长。

在北美，披衣菌感染感染诊断市场预计将稳定成长。

预计北美地区将在披衣菌感染感染诊断市场中占据主要份额。披衣菌感染感染盛行率的不断上升以及主要製造商的新产品创新将推动该地区的披衣菌感染感染诊断产业。例如，根据 CDC 的数据，2021 年美国约有 160 万人感染披衣菌感染。此外，不断增加的产品创新和核准正在推动该地区披衣菌感染感染诊断市场的快速成长。 2022 年 5 月，雅培的 Alinity m STI 检测获得 FDA核准。 Alinity m STI 需要单一拭子样本或尿液样本来诊断披衣菌感染。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章披衣菌感染感染诊断市场：依产品类型

  • 介绍
  • 诊断
  • 疗法

第六章披衣菌感染感染诊断市场：依测试类型

  • 介绍
  • 文化测试
  • 核酸增幅检查
  • 直接萤光抗体检测
  • 血清学检测
  • 其他的

第七章披衣菌感染感染诊断市场：依最终用户分类

  • 介绍
  • 医院
  • 诊断中心
  • 其他的

第八章披衣菌感染感染诊断市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Mayo Clinic
  • BioMerieux Clinical Diagnostics
  • Quidel
  • The Native Antigen Company
  • Abbott Molecular
  • Roche Diagnostics
  • Creative Diagnostics
  • Cepheid
  • Aetna
简介目录
Product Code: KSI061616141

The chlamydia infection diagnostics market was valued at US$1,211.526 million in 2022.

Chlamydia diagnostics are tests and procedures used to identify the chlamydia trachomatis bacteria's presence in an individual. It is a sexually transmitted disease and is asymptomatic, which means the symptoms of chlamydia are not seen but the person can still be infected. Therefore, early diagnosis and treatment of chlamydia disease is important.

Driving factors for the chlamydia infection diagnostics market

The major factor influencing the growth of the chlamydia infection diagnostics market is the rising testing frequency and the increase in demand for quick and reliable testing. Molecular diagnostics have experienced a huge surge in the chlamydia infection diagnostics industry. To meet the rising demand there have been various technological advantages, including quick and point-of-care testing options. Further, various government initiatives are also fueling the chlamydia infection diagnostics market growth. For instance, the National Chlamydia Screening Program (NCSP) by the government of the United Kingdom.

Growing prevalence of sexually transmitted disease

Chlamydia infection has been growing at a rapid pace. This growth is majorly due to changing sexual behaviour and the lack of awareness of STDs essentially chlamydia among individuals. If chlamydia is untreated, it can affect the human body and cause serious health complications. Therefore, the demand for accurate and timely diagnosis is significantly increasing. Additionally, the need for novel diagnostic approaches to treat antibiotic-resistant strains to treat chlamydia bacteria has increased. Owing to this various chlamydia infection diagnostics industry players are focusing on new product development.

Increase in people suffering from chlamydia infection

There has been significant growth in people suffering from chlamydia infection owing to the lack of awareness among individuals and changing sexual behavior. For instance, as per the CDC data published in 2021, 1,644,416 cases of chlamydia were reported, making it one of the most prevalent diseases in the United States. This signifies that there were 495.5 cases per 100,000 people in the United States in 2020. The growing rate of this disease is increasing the diagnosis and treatment with the use of advanced tests and is expected to fuel the chlamydia infection diagnostics market growth.

Rising global agency support

According to the report published by The WHO in the year 2020, the agency plans to reduce the STI prevalence around the globe. Owing to this, the diagnosis and treatment for chlamydia has increased significantly. Furthermore, various councils and colleges have been focusing on promoting the diagnosis and treatment of various STDs especially chlamydia, which has a long-term effect on the female body. If chlamydia is diagnosed at an earlier stage it can be treated easily. Various government initiatives have been taking place to eradicate the cases of chlamydia globally.

Growing popularity of the Nucleic Acid Amplification Test (NAAT)

The Nucleic Acid Amplification Test is a molecular test that detects DNA. To diagnose chlamydia infection NAAT detects chlamydia trachomatis RNA or DNA in biological sample. The NAAT method is more sensitive and specific, and it's performed on vaginal swabs from women and urine for both males and females. Additionally, in March 2022, the Binx Health IO CT/N assay was approved by the FDA at point-of-care settings in various end users. Product approvals further increase the prominence of NAAT in the chlamydia infection diagnostics market

Development of advanced diagnostic technologies

The development of various advanced diagnostic technologies like molecular diagnostic tests is one of the key factors fueling the chlamydia infection diagnostics market. This has led to the development of various accurate and sensitive chlamydia diagnostic tests. For instance, Roche collaborated with NICE to introduce guidelines for molecular diagnostic usage for the diagnosis of chlamydia. These guidelines have helped diagnostic tests to be standardized in the United Kingdom. The increasing healthcare expenditure globally is leading to various investments, including technologically advanced diagnostic facilities.

Proliferating applications in hospitals

Hospitals are anticipated to hold the maximum chlamydia infection diagnostics market share. The effortless accessibility of infrastructure and qualified physicians are the key growth drivers for this development. There are huge numbers of patients who require diagnosis in hospitals and the easy availability of screening tests in hospitals to detect chlamydia is fueling the chlamydia infection diagnostics market growth. Moreover, diagnostic centers are also anticipated to grow significantly due to the surging application of molecular diagnosis of chlamydia trachomatis including the application of NAAT.

In North America, it is projected that the chlamydia infection diagnostics market will grow steadily.

The North American region is anticipated to secure a sizable chlamydia infection diagnostics market share. The regional chlamydia infection diagnostics industry will be fueled by the increasing prevalence of chlamydia infection and new product innovation by key manufacturers. For instance, according to the CDC, nearly 1.6 million people in the United States were infected with chlamydia in 2021. Furthermore, the increasing product innovation and approvals are surging the growth of the chlamydia infection diagnostics market in the region. In May 2022, Abbott's Alinity m STI assay received approval from the FDA. Alinity m STI requires one swab sample or urine sample to diagnose chlamydia.

Market Key Developments

  • In May 2023, The Visby Medical Sexual Health Test, a polymerase chain reaction (PCR) diagnostic test for the identification of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in women, has been approved by the Food and Drug Administration (FDA).
  • In May 2022, BD introduced the BD COR MX instrument which is an automated high-throughput molecular diagnostic platform in the United States.
  • In April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) collaborated with Visby Medical Inc., and The Body Agency Collective to improve STD diagnosis and treatment including chlamydia.

Segmentation:

By Product Type

  • Diagnostics
  • Therapeutics

By Test Type

  • Culture Tests
  • Nucleic Acid Amplification Test
  • Direct Fluorescent Antibody Test
  • Serology Tests
  • Others

By End-User

  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Diagnostics
  • 5.3. Therapeutics

6. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY TEST TYPE

  • 6.1. Introduction
  • 6.2. Culture Tests
  • 6.3. Nucleic Acid Amplification Test
  • 6.4. Direct Fluorescent Antibody Test
  • 6.5. Serology Tests
  • 6.6. Others

7. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Diagnostic Centers
  • 7.4. Others

8. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Mayo Clinic
  • 10.2. BioMerieux Clinical Diagnostics
  • 10.3. Quidel
  • 10.4. The Native Antigen Company
  • 10.5. Abbott Molecular
  • 10.6. Roche Diagnostics
  • 10.7. Creative Diagnostics
  • 10.8. Cepheid
  • 10.9. Aetna